Accumulating evidence have demonstrated that increased expression of TGF-β1 is associated with tumor aggressiveness and poor prognosis in HCC13, bladder cancer14, breast cancer15, prostate cancer16 and cholangiocarcinoma17. This evidence concerns the gene TGFB1 and neoplasm.